# Coherus Oncology, Inc. (CHRS)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/coherus-oncology-inc/ JSON: https://steadybase.io/company/coherus-oncology-inc.json Checked Nov 11, 2026. Latest filing read: Nov 9, 2026.

## Company

- Legal name: Coherus Oncology, Inc.
- Ticker: CHRS (Nasdaq)
- SEC CIK: 0001512762
- Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
- Headquarters: Redwood City, CA
- Fiscal year ends: December 31
- SEC filer category: Accelerated filer<br>Smaller reporting company
- Website: coherus.com
- LinkedIn: https://www.linkedin.com/company/coherus-biosciences
- Next earnings date: Nov 9, 2026

## Key facts

- Revenue: $42.2M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 9, 2026). Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/0001104659-26-025308-index.html
- Operating income: -$181.1M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 9, 2026). Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/0001104659-26-025308-index.html
- Net income: $168.0M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 9, 2026). Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/0001104659-26-025308-index.html
- SG&A: $100.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 9, 2026). Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/0001104659-26-025308-index.html
- Employees: 147 as of , as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- Shares outstanding: 154,538,277 as of Oct 31, 2026 (10-Q filed Nov 9, 2026). Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926124572/0001104659-26-124572-index.html
- Auditor: Ernst & Young LLP, San Francisco, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm

## Business

We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma (“NPC”) and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners, driving sales multiples and synergies from proprietary combinations.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $42.2M | -$181.1M | $168.0M | $100.6M |
| Dec 31, 2024 | $26.4M | -$199.7M | $28.5M | $125.5M |
| Dec 31, 2023 | $1.2M | -$215.8M | -$237.9M | $120.5M |
| Dec 31, 2022 | $211.0M | -$256.9M | -$291.8M | $198.5M |
| Dec 31, 2021 | $326.6M | -$263.9M | -$287.1M | $169.7M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/coherus-oncology-inc.json

## Officers and directors

- Dennis M. Lanfear, President & CEO. Source: Form 4 filed Jun 2, 2026, https://www.sec.gov/Archives/edgar/data/1512762/000110465926069621/0001104659-26-069621-index.htm
- Bryan J. McMichael, Chief Financial Officer. Source: Form 4 filed Jun 2, 2026, https://www.sec.gov/Archives/edgar/data/1512762/000110465926069622/0001104659-26-069622-index.htm
- Bryan McMichael, Chief Financial Officer. LinkedIn: https://www.linkedin.com/in/bryan-mcmichael-807659. Source: 10-K filed Mar 9, 2026, https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- Ali J. Satvat, Director. Source: 10-K filed Mar 9, 2026, https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- Charles W. Newton, Director. Source: 10-K filed Mar 9, 2026, https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- Georgia Erbez, Director. Source: 10-K filed Mar 9, 2026, https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- Jill O’Donnell-Tormey, Director. Source: 10-K filed Mar 9, 2026, https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- Lee N. Newcomer, Director. Source: 10-K filed Mar 9, 2026, https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- Mats Wahlström, Director. Source: 10-K filed Mar 9, 2026, https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- Michael Ryan, Director. Source: 10-K filed Mar 9, 2026, https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- Rita Karachun, Director. Source: 10-K filed Mar 9, 2026, https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- Jill O'Donnell-Tormey, Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/1512762/000110465926045251/chrs-20260527xdef14a.htm
- Mats L. Wahlström, Board member (per proxy). Source: DEF 14A filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/1512762/000110465926045251/chrs-20260527xdef14a.htm
- Rita A. Karachun, Board member (per proxy). Source: DEF 14A filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/1512762/000110465926045251/chrs-20260527xdef14a.htm

## Recent 8-K events

- Nov 9, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926124511/chrs-20261109x8k.htm
- Oct 29, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926119912/chrs-20261028x8k.htm
- Aug 28, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926103316/chrs-20260828x8k.htm
- Aug 17, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926097951/chrs-20260817x8k.htm
- Aug 17, 2026: Item 1.01, Entry into a material definitive agreement; Item 1.02, Termination of a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926097949/chrs-20260817x8k.htm
- Aug 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/chrs-20260805x8k.htm
- Jun 15, 2026: Item 4.01, Changes in registrant's certifying accountant; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926074090/chrs-20260612x8k.htm
- Jun 1, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926068615/chrs-20260527x8k.htm
- May 11, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/chrs-20260511x8k.htm
- Mar 9, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/chrs-20260309x8k.htm

## What management said

- "The strategic prioritization of esophageal cancer as our best-in-disease focus for tagmokitug, together with the Transition Services Agreement wind-down and the toripalimab process transfer completion, provides an ideal opportunity to right-size the organization and deliver financial benefits that flow directly from this prioritization" Denny Lanfear, Chief Executive Officer of Coherus Oncology (8-K filed Nov 9, 2026). Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926124511/chrs-ex99d1.htm
- "The financial benefits of right-sizing the organization and reducing the scope of our forward-focused efforts provide substantial and durable benefits to our operating model" Bryan McMichael, Chief Financial Officer of Coherus Oncology (8-K filed Nov 9, 2026). Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926124511/chrs-ex99d1.htm
- "During the second quarter we continued to pursue our science-driven clinical development strategy, creating multiple avenues for long-term value creation, and look forward to further maturation of data with both tagmokitug and casdozokitug" Denny Lanfear, Chairman and Chief Executive Officer (8-K filed Aug 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/chrs-20260805xex99d1.htm

## Latest filings

- 8-K filed Oct 29, 2026: https://www.sec.gov/Archives/edgar/data/1512762/000110465926119912/chrs-20261028x8k.htm
- 10-K filed Mar 9, 2026: https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm
- 10-Q filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/1512762/000110465926091262/chrs-20260630x10q.htm
- DEF 14A filed Apr 20, 2026: https://www.sec.gov/Archives/edgar/data/1512762/000110465926045251/chrs-20260527xdef14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/